Klinika za psihijatriju Vrapce

The Department for Biological Psychiatry and Psychogeriatrics at Klinika za psihijatriju Vrapce concentrates on neurodegenerative conditions that affect the brain’s structure and function.

• Evaluation of agitation in patients with Alzheimer’s dementia
• Study of psychosis linked to Alzheimer’s disease
• Assessment of cognitive decline in mild to moderate Alzheimer’s disease
• Investigation of long‑term safety of novel agents for cognitive impairment in Alzheimer’s patients

These trials aim to test new therapies that reduce behavioral symptoms, improve cognition, and verify long‑term tolerability in elderly populations.

Research here targets disruptive behaviors that compromise daily living and caregiver burden.

• Trials addressing agitation associated with Alzheimer’s dementia
• Interventions for mania in Bipolar‑I disorder
• Adjunctive treatment of tardive dyskinesia in individuals with schizophrenia or related mood disorders
• Evaluation of agents for psychosis associated with Alzheimer’s disease

The purpose is to identify effective medications that calm agitation, control manic episodes, and lessen involuntary movements, thereby enhancing patient safety and quality of life.

The site conducts extensive work on core psychiatric illnesses that require long‑term management.

• Studies on symptom relief in schizophrenia
• Evaluation of acute treatment for Manic episodes in Bipolar I Disorder
• Adjunctive therapy trials for Major Depressive Disorder
• Research on overlapping conditions such as schizoaffective disorder

Objectives include testing novel compounds for efficacy, monitoring safety, and improving overall functional outcomes for patients with severe mental illness.

This field explores underlying mental processes that manifest as clinical symptoms.

• Measurement of agitation using standardized inventories
• Quantification of psychosis severity through clinician‑rated scales
• Assessment of cognitive impairment and global functioning in dementia
• Monitoring of motor disturbances such as tardive dyskinesia

The trials seek to refine diagnostic criteria, evaluate therapeutic impact on these phenomena, and support better clinical decision‑making.